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CD1a down-regulation in primary invasive ductal breast carcinoma may predict regional
lymph node invasion and patient outcome
Aims: CD1a is a molecule belonging to the highly
conserved group of CD1 proteins. Its expression in
dendritic cells is related to the presentation of tumour-
derived glycolipid antigens to T cells and, consequently,
the development of a successful antitumour response.
The aim was to investigate the presence of CD1a+ cells
in both primary tumours and lymph nodes (LN) of
a series of 35 invasive ductal carcinomas by both
immunohistochemistry and reverse transcription-poly-
merase chain reaction.
Methods and results: CD1a antigen was more expressed
in N0 than N1 breast cancer (P < 0.0001) in both
primary lesions and LN metastases and correlated
positively and significantly with oestrogen (ER) (P =
0.0025) and progesterone (P = 0.0226) receptor (PR)
status, as well as CD4+ and CD8+ T-lymphocyte
infiltration.
Conclusions: This is the first report to show a link
between CD1a+ mononuclear cells in breast cancer
and in paired LN metastases. The positive and signifi-
cant correlations between the number of CD1a+ cells
and positivity of the primary tumour for ER and PR
suggest a possible role for CD1a as a prognostic marker
for breast cancer, raising the possibility that hormone
receptor-positive breast cancer patients may have a
better prognosis in the presence of greater dendritic cell
infiltration.
Keywords: antitumour response, breast cancer, CD1a, dendritic cells, ductal carcinoma
Abbreviations: BM, Barrett’s metaplasia; DC, dendritic cell; ER, oestrogen receptor; IDC, invasive ductal carcinoma;
LN, lymph node; PCR, polymerase chain reaction; PR, progesterone receptor; RT, reverse transcriptase
Introduction
CD1a is a molecule belonging to the highly conserved
and closely related group of CD1 proteins. Its
expression in dendritic cells (DCs) is functionally
important for presentation of tumour-derived glyco-
lipid antigens to T cells and the subsequent develop-
ment of a successful antitumour response.1 Analyses
of DCs in tumour-free and tumour-containing lymph
nodes (LN) from breast cancer have already been
performed. Coventry and Morton2 in a 5-year follow-
up study of breast cancer patients have shown that
although more patients were alive at the 5-year time
point in the group with a greater CD1a+ cell density,
this was without statistical significance. On the other
hand, Poindexter and collaborators3 have shown no
significant differences in the number of CD1a+ cells
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between metastasized and non-metastasized sentinel
LNs of breast cancer. Furthermore, Treilleux et al.4
have shown that CD1a expression in primary breast
cancers does not correlate with any of the
clinicopathological variables, while the infiltration of
plasmacytoid DCs has adverse prognostic significance.
Nevertheless, there are no studies on CD1a+
mononuclear cell status in primary breast lesions
with or without in situ components and regional LN
tissue.
We have recently found that CD1a may be expressed
in the cells of Barrett’s metaplasia (BM)5 and the lack of
expression of this antigen may predict its evolution
toward oesophageal adenocarcinoma.6 Indeed, CD1a
may be expressed not only by DCs but also by
transformed epithelial cells in BM. The interaction
between DCs, CD1a-immunoreactive epithelial cells
and T cells might potentiate the antitumour defence,
at least in BM.7
In the present study, the presence of CD1a at
both primary tumour and LN level was investigated
in a homogeneous group of invasive ductal carcin-
omas (IDC) of the breast and CD1a immunoreactiv-
ity was correlated with clinical and pathological
data.
Materials and methods
tissue
Eighteen N0, eleven N1 and six N2 formalin-fixed
paraffin-embedded blocks of IDC clinical and patholog-
ical data were collected from the archives of the Service
of Pathological Anatomy, Civico Hospital, Palermo,
Italy. Standard informed ethical consent to use tissue
for research was given.
immunohistochemistry
Tissue sections (3 lm thick) from tumour and
neighbouring areas were cut and deparaffinized for
immunohistochemistry for each antigen. In order to
minimize geographical variation, three non-serial
sections were evaluated for each antigen. Immuno-
histochemistry was performed using monoclonal
antibodies against CD1a (clone O10; Dako, Glostrup,
Denmark), oestrogen (ER) (clone 1D5; Dako) and
progesterone (clone PgR 636; Dako) receptor (PR),
Ki67 (clone MIB-1; Dako), cErbB2 (HercepTest;
Dako), CD4 (M0716; Dako), CD8 (M7103; Dako)
and CD20 (M0755; Dako), revealed by an avidin–
biotin complex system (Labelled Streptavidin–Biotin2;
Dako). Tissue specimens were divided in two groups:
the first from patients without detectable LN meta-
stases (N0), the second from patients with LN
metastases (N+ = N1 + N2). In each group, histolog-
ical type, tumour grade, T and N stage according
to the most recent TNM classification, age of the
patients, tumour size (in mm) and the number of
metastatic LNs were registered in a blinded manner.
Three independent observers (F.C., F.R. and L.M.)
evaluated the immunohistochemical results and semi-
quantified the percentage of positive cells for each
specimen. The mean value of the three percentages
was considered in this study. Ten high-power fields
(field area 1.016 mm2) were examined in each tissue
slide and counting of the cells was performed at · 40
magnification following detection of the nature of
the cells, for areas both inside and surrounding the
tumour.
rna extraction
Total RNA was extracted using the QuickPrep kit from
Amersham Biosciences (Milan, Italy) following the
manufacturer’s instructions. The extraction of each
specimen was performed on a tissue slice of about
50 mg. RNA was used for polymerase chain reac-
tion (PCR) analysis only if the absorbance ratio
(A260 ⁄ A280 ratio) was > 1.6.
reverse transcriptase-pcr
DNase-treated (AMPD1 DNAse; Sigma-Aldrich, Milan,
Italy) total RNA aliquots (2 lg total RNA) were
subjected to reverse transcriptase (RT)-PCR analysis
using the Ready-to-Go RT-PCR kit. RT-PCR was
performed using the Ready-To-Go RT-PCR beads
(Amersham Biosciences). The reaction was carried
out using a two-step protocol, with a MyCycler
thermal Cycler (BioRad, Milan, Italy). RT-PCR was
carried out by mixing 2 g of total RNA, 0.5 lg of
pd (T)12-18, 1 lg of pd (N)6 with RNase-free water.
The reaction comprised a reverse transcription step
of 30 min (42C), followed by inactivation of the
enzyme at 95C (5 min). Then 100 pm of specific
primers was added and the reactions were cycled for
95C for 2 min, then 35 cycles of 95C for 60 s, 60C
for 60 s, 72C for 90 s, with a final extension at 72C
for 10 min.
Primers used in this study were:
CD1a forward: 5¢-TGAAGTATGGCAACGCCGAT-3¢;
CD1a reverse: 5¢-AAGCCATACTTCTTGTCGCG-3¢;
product size 645 bp;
b2-microglobulin forward: 5¢-AAGGTGAAGGTCGG
AGTCAA-3¢;
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b2-microglobulin reverse: 5¢-AAGTGGTCGTTGAGG
GCAAT-3¢; product size 742 bp.
b2-microglobulin was preferred as a housekeep-
ing gene instead of glyceraldehyde-3-phosphate
dehydrogenase and b-actin because of the better
linearity of expression in all the experimental
conditions. The identity of PCR products was con-
firmed by incubation with the appropriate restriction
enzyme and subsequent visualization of the cleavage
products on a 2% ethidium bromide-stained agarose
gel.
statist ical analysis
Data obtained from the evaluation of the immuno-
reactivity, as well as from RT-PCR densitometry, were
plotted using Microsoft Excel software (Microsoft,
Redmond, WA, USA). Statistical analyses were carried
out using GraphPad Prism 4.0 package (GraphPad
Inc., San Diego, CA, USA). Statistical analyses were
performed using non-parametric tests in order to
compare groups that did not fit the normal distribution.
To evaluate the significance of differences of CD1a
expression between the N0 and N+ populations, at the
levels of both primary tumour and LN, the Mann–
Whitney test was used. Correlation analysis between
CD1a expression at the tumour epithelial cell (CD1aT)
and nodal tissue cell (CD1aN) level and the clinico-
pathological variables of the tumour was performed
using the non-parametric Spearman’s test, which gives
a correlation coefficient (Spearman r) and a P-value to
establish the significance of the analysed correlation.
For correlation graphs, linear regression was also
calculated to reflect the type of correlation between
the variables detected. Data were considered significant
at an a-level of 5%. Moreover, in order to have an
indication of the variability of immunoreactivity data
determined by the three different observers, the coeffi-
cient of variation was calculated using both the inter-
and intra-observers j statistics.
Results
express ion of clinicopathological variables
in the patient population
To analyse the features of the primary tumours,
immunohistochemical evaluation was performed as
described above. As shown in Table 1, immunohisto-
chemical data on receptor status, MIB-1 and erbB2
expression, and CD1a positivity were plotted together
with clinical and pathological data (tumour size, node
status, nuclear grading).
cd1a immune profile
Data on CD1a expression were evaluated in both
primary tumours and LNs. Figure 1 shows a panel
of representative immunohistochemical microphoto-
graphs of CD1a expression at the level of both primary
tumour and LN in the three subgroups (N0, N1, N2).
Immunohistochemical analysis of CD1a in LN tissue
showed a greater number of CD1a+ cells present in N0
LN (Figure 1A) compared with N+ ones (Figure 1B,C).
As regards the localization of the antigen in the
primary tumour lesion for both N0 and N+ groups,
CD1a+ mononuclear cells were more represented in
the stroma associated with N0 tumours (Figure 1D,E)
than with N1 tumours (Figure 1F) and, in some cases,
reactivity was also located at both the stromal and
tumour cell level (Figure 1E). Epithelial elements of
in situ components in five of 13 N0 and three of
12 N+ primary tumours located far from the primary
focus showed no or very weak immunoreactivity (not
shown).
evaluation of the inflammatory infiltrate
in primary tumours
In order to assess the presence of CD4+, CD8+ and
CD20+ cells in the primary tumours studied, immuno-
histochemical analysis was performed. Figure 2 shows
representative panels of CD4 immunoreactivity in
N0 (Figure 2A) and N+ (Figure 2B) primary lesions.
As can be seen, and as summarized in Table 1, the
number of CD4-expressing cells is higher in N0 rather
than in N+ lesions. Moreover, a similar pattern of
immunopositivity was detected for CD8+ cells, which
are more numerous in N0 (Figure 2C) than in N+
(Figure 2D) primary tumours. CD20 levels were similar
in both N0 and N+ subgroups (not shown).
cd1a immunoposit ivity: correlation with
clinical and pathological data
To assess the significance of the differences in the
expression levels of the antigen, the Mann–Whitney
test was chosen to compare the two populations (N0
and N+) with respect to the expression of CD1a antigen
evaluated by immunohistochemistry. Interobserver j
statistics showed a value of 0.86 and intra-observer j
statistics showed a value of 0.97.
In primary tumours, CD1a was more expressed in
N0 than in N+ cases (Figure 3A). This result was
statistically significant (P < 0.0001). In Figure 3B,A
similar trend is schematized for the immunological
reactivity to CD1a in LNs, because in N0 LNs the
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Table 1. CD1a immune profile of 35 patients with invasive breast cancer of ductal type
Age Grading T N LN no.
ER,
%
PR,
%
MIB1,
% cerb-B2
CD1aT,
%
CD1a n,
%
CD4T,
%
CD8T,
%
CD20T,
%
54 G2 T1c N0 0 ⁄ 19 80 70 10 0 60 70 65 40 10
45 G2 T1c N0 0 ⁄ 22 30 50 10 0 60 80 50 30 5
64 G2 T1c N0 0 ⁄ 33 60 60 30 0 60 70 45 30 12
55 G2 T1c N0 0 ⁄ 18 50 40 20 0 60 90 70 25 8
74 G2 T1c N0 0 ⁄ 25 50 30 10 0 60 60 55 35 10
68 G2 T2 N0 0 ⁄ 14 40 80 30 1 30 60 60 25 5
59 G2 T2 N0 0 ⁄ 15 70 70 10 0 30 50 45 15 8
78 G2 T2 N0 0 ⁄ 20 20 80 10 0 30 70 60 20 5
68 G2 T2 N0 0 ⁄ 16 90 60 5 0 30 60 45 20 10
51 G3 T2 N0 0 ⁄ 12 20 30 5 2 50 50 55 15 6
60 G3 T2 N0 0 ⁄ 18 30 10 10 1 60 70 70 35 7
50 G3 T2 N0 0 ⁄ 20 90 50 20 0 50 60 60 30 8
61 G3 T2 N0 0 ⁄ 18 50 20 5 2 60 70 65 35 7
69 G2 T1 N0 0 ⁄ 20 70 60 45 0 60 70 65 25 10
45 G3 T3 N0 0 ⁄ 16 30 30 70 2 40 50 50 20 3
47 G2 T4 N0 0 ⁄ 16 20 5 40 0 50 60 50 35 3
77 G1 T1 N0 0 ⁄ 17 5 5 60 0 60 70 70 20 10
29 G2 T1 N0 0 ⁄ 14 60 50 55 2 50 70 60 35 6
46 G2 T1c N1 12 ⁄ 31 30 50 10 1 5 5 5 7 5
78 G2 T1c N2 8 ⁄ 17 0 0 5 0 0 15 7 3 8
50 G2 T2 N2 2 ⁄ 20 0 0 70 2 0 10 3 5 10
48 G2 T2 N2 5 ⁄ 15 0 0 20 1 10 10 8 5 3
59 G2 T2 N1 14 ⁄ 23 0 0 5 0 0 5 4 3 3
58 G2 T2 N2 7 ⁄ 19 0 0 30 2 0 0 3 5 3
67 G2 T2 N2 3 ⁄ 18 80 20 10 1 5 5 4 6 10
51 G2 T2 N1 4 ⁄ 28 0 0 20 2 0 10 5 7 5
70 G2 T2 N2 2 ⁄ 10 50 70 10 0 0 5 10 10 5
56 G3 T2 N1 12 ⁄ 18 0 15 40 0 5 10 8 5 7
50 G3 T2 N1 10 ⁄ 22 0 0 50 1 0 10 5 3 4
66 G3 T2 N1 12 ⁄ 25 0 10 20 0 0 10 6 5 7
43 G2 T3 N1 7 ⁄ 16 50 20 55 1 0 15 10 8 10
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expression levels were significantly higher than in
N+ cases (P < 0.0001). Possible correlations between
CD1a expression and clinical and pathological fea-
tures of the tumours were then evaluated, in order to
determine the feasibility of using this molecule as an
additional marker for better therapeutic classification
of patients. When performing correlation analysis
between CD1a expression and nodal status, the
expression levels of the molecule were compared at
the tumour level with the nodal status as well as
the intranodal expression of CD1a with respect to the
presence of nodal metastases. In both cases, the
correlation was negative and reached statistical sig-
nificance (r = )0.8483 and P < 0.0001 for CD1aT;
r = )0.8635 and P < 0.0001 for CD1aN). Therefore,
the data indicate a significant correlation between
reactivity to CD1a antigen (expressed by mononuclear
cells both surrounding the primary tumour and at
LN level) and absence of LN metastases. Correlation
analysis was then performed between the expression
of CD1a and the tumour receptor status (Figure 4).
The expression of CD1a correlated with the reac-
tivity to ER (Figure 4A,C) (r = 0.3398, P = 0.0458
for CD1aT; r = 0.3445, P = 0.0427 for CD1aN).
Figure 4B,D shows the results of the same analy-
sis performed with regard to PR status. For this
variable, also, the correlation was statistically sig-
nificant (r = 0.4242, P = 0.0111 for CD1aT; r =
0.5355, P = 0.0009 for CD1aN). Thus, correlation
studies showed a significant correlation between the
expression of CD1a at both primary tumour and
nodal level, and reactivity for ER and PR status.
Correlation analyses with the other clinical and
pathological parameters did not reach statistical
significance, even if indicating a trend of lower
CD1a expression for cErbB2+ tumours (r =
)0.1406, P = 0.4204 for CD1aT; r = )0.1827,
P = 0.2935 for CD1aN; not shown).
To evaluate the statistical significance of the differ-
ences noted in the expression of CD4 and CD8 in breast
cancers, with respect to nodal status, statistical analysis
using the Mann–Whitney test was performed. As
depicted in Figure 2, CD4+ cells were more present in
N0 rather than N+ tumours, and this difference
reached statistical significance (P < 0.0001). This
trend was confirmed also for CD8 expression, with
statistical significance (P < 0.0001). On the other
hand, no significant differences in CD20 immunoposi-
tivity were observed between N0 and N+ tumours
(P = 0.1696). Correlation analysis was also performed
between the positivity of primary lesions to CD1a and
to CD4 and CD8. In N0 tumours, expression of CD1a
antigen positively and significantly correlated with the
presence of CD4+ cells (r = 0.8643, P < 0.0001). A
positive correlation was also determined between
CD1a expression in N0 tumours and the number
of CD8+ cells, which reached statistical significance
(r = 0.8358, P < 0.0001). On the other hand, no
correlation was found between CD1a expression and
CD20 expression in N0 tumours (r = 0.2883, P =
0.0930).
rt-pcr analysis of cd1a express ion at the
primary tumour level
RT-PCR was performed on a limited number of primary
tumours (N0 = 4; N+ = 4). Normalized densitometry
data confirmed that the expression of CD1a was higher
in N0 than in N1 tumours (Figure 5A,B). Moreover,
the data reached statistical significance when the
differences in the expression levels of CD1a between
N0 and N1 tumours (P = 0.0002, as assessed by
Mann–Whitney test) were analysed (Figure 5B). Final-
ly, correlation analysis was performed between the
normalized expression levels of CD1a mRNA and
the paired immunopositivity in primary tumours.
Table 1. (Continued)
Age Grading T N LN no.
ER,
%
PR,
%
MIB1,
% cerb-B2
CD1aT,
%
CD1a n,
%
CD4T,
%
CD8T,
%
CD20T,
%
67 G3 T1 N1 4 ⁄ 15 70 5 40 1 5 10 4 10 8
39 G2 T2 N1 5 ⁄ 14 50 5 55 0 0 10 3 4 5
60 G3 T2 N1 2 ⁄ 12 80 5 15 1 5 10 8 3 3
50 G3 T4 N1 19 ⁄ 24 40 40 20 0 5 10 5 5 8
LN no., Number of regional lymph nodes with metastasis; ER, oestrogen receptor status; PR, progesterone receptor status;
MIB1, proliferation activity of the carcinoma cells; c-ERB-B2 status, CD1a T, percentage of carcinoma cells in the primary
tumour expressing CD1a; CD1a N, percentage of carcinoma cells in the regional lymph node expressing CD1a.
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C F
B E
A D
Figure 1. Representative immune profile of CD1a antigen expression in primary lesions and regional lymph nodes: A, histological section from
an N0 breast cancer-draining lymph node showing strong expression of CD1a. B, Scarce CD1a reactivity in a N+ lymph node. C, Higher
magnification shows few positive elements near metastasis (top right corner). D, High number of CD1a+ mononuclear cells in N0 primary
tumour. E, Higher magnification showing CD1a+ cells localized both in and around tumours. F, Weaker CD1a positivity in a N+ primary
invasive ductal carcinoma.
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A  B  
C  D  
Figure 2. A greater number of CD4+ and CD8+ lymphocytes in N0 than in N+ primary breast cancers. A, CD4+ cells in N0 tumour. B, Low CD4
in a N+ tumour. C, CD8+ cells in a N0 primary lesion. D, CD8 in a N+ primary tumour.
P < 0.0001
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Figure 3. Differential expression of CD1a antigen in primary tumours and lymph nodes, grouped for their nodal status. A, CD1a expression
levels in primary tumours with respect to node status (N0 and N+). B, CD1a expression in lymph nodes (N0 and N+). Data are represented
as mean with SD; significance of difference between the two populations calculated by Mann–Whitney test.
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Statistical analysis revealed a positive and significant
correlation (P = 0.0046; r = 0.9011). The present
results therefore strongly suggest that CD1a expression
is higher in N0 than in N+ breast cancers, at both the
protein and mRNA levels.
Discussion
Immunohistochemical data of the present study
strongly suggest that there is a link between the
expression of CD1a and the node status of the tumour
in ductal infiltrating breast cancer. On immunohisto-
chemistry, CD1a is expressed more in the stroma of
N0 than in N+ breast cancers (P < 0.0001) and its
expression in infiltrating mononuclear cells correlates
significantly with the positivity of tumour cells for
ER (P = 0.0458) and PR (P = 0.0111). Moreover, the
same significance was detectable at nodal level, with a
higher number of CD1a+ mononuclear cells in N0 than
in N1 LNs (P < 0.0001). In the levels of CD1a antigen
in lymph nodes, a significant positive correlation was
also observed with the expression of OR (P = 0.0427)
and PR (P = 0.0009) at the primary tumour level.
Moreover, high CD1a+ immunoreactivity was localized
in epithelial elements of invasive components, whereas
epithelial elements of in situ components of breast
cancer far from the primary focus showed no or very
weak reactivity. These are new data and resemble those
shown for Barrett’s metaplastic cells.8,9 The present
data therefore suggest that CD1a is expressed more
frequently in N0 tumours and LNs than in N+ ones,
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Figure 4. Correlation analysis
of CD1a antigen expression at
both primary lesion and lymph
node level and the receptor
status of the tumours.
A, Correlation between CD1a
and oestrogen receptors (ER) in
primary tumours. B, Correla-
tion between CD1a and
progesterone receptors (PR) in
primary tumours. C, Correla-
tion between CD1a and ER
in lymph node metastases.
D, Correlation between CD1a
and PR in lymph node
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Figure 5. Representative reverse transcriptase-polymerase chain
reaction analysis of four cases of primary lesions showing higher
expression of CD1a (B) in two N0 compared to two N1 infiltrating
ductal carcinomas. A, Controls with b2-microglobulin. C, Normalized
mRNA levels of CD1a are significantly higher in N0 than in N1
tumours. Data are shown as mean and SD. Significance of differences
evaluated using the Mann–Whitney test.
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suggesting that in the first a genuine immune response
is taking place.
The differences in the expression levels of CD1a
protein between N0 and N+ tumours were confirmed
at the mRNA level. In fact, the expression of CD1a
was higher in N0 than in N+ tumours, as assessed
by densitometry of RT-PCR products normalized for a
housekeeping gene. This result, although obtained on a
limited fraction of the study population, confirmed at
the messenger level the lower CD1a expression in N1
than in N0 tumours, observed with immunohisto-
chemistry.
The immunohistochemical evaluation of the inflam-
matory infiltrate in primary tumours allowed the
determination of significant differences in the number
of CD4+ and CD8+ cells between N0 and N1 tumours,
whereas CD20 immunopositivity did not vary signifi-
cantly.
The data presented thus far allow the establish-
ment of an association between the nodal status of
the tumours and the levels of expression of CD1a
in mononuclear cells both in the peritumoral
stroma and in draining LNs. These data allow the
correlation of these two well-established parameters
with the investigated marker, thus also suggesting
for breast cancer a possible positive role for CD1a
expression.
The establishment of an immune response against
tumours may depend on the capacity of DCs to
transfer antigens to LNs, where antigen presentation
to T cells may take place.10 One of the requirements
for glycolipids to be efficient immunogens is the
maintenance of the antigen-bearing molecules for a
sufficient time to allow T-cell recognition. In vitro
data suggest that the half-life of CD1–antigen com-
plexes is 24 h, which is adequate for T-cell stimu-
lation.8
The process of differentiation leading to maturation
of DCs in the host response also includes a differential
localization of competent immune cells within the
tumour or the peritumoral area. In fact, mature DCs
locate specifically to peritumoral areas, whereas imma-
ture cells are also present within the tumour in breast
cancer.9,11 Interestingly, the migration of competent
DCs to the lymph nodes, where the interaction with
specific T cells may take place, has been shown to be
enhanced in pN0 cases compared with pN+ tumours in
oral squamous cell carcinoma.12
The present data are the first to show that: (i) CD1a
is expressed not only in LNs but also in primary
lesions of IDC, and its absence may predict the
existence of LN metastases; (ii) expression of this
antigen significantly and positively correlates with ER
and PR, thus supporting the hypothesis that an
increased number of mononuclear cells expressing
this molecule both in primary tumour and LN should
be considered as a favourable prognostic marker for
breast cancer.
A review of the literature demonstrates that the
presence of DCs in lymph nodes is a prognostic
predictive factor.4,13 Moreover, it has recently been
postulated that in breast cancer DCs show lower
CD1a expression14 and an increase in spontaneous
apoptosis,15 findings which support the present data
on the predictive value of CD1a expression, not only
in LNs, but also in primary tumours, as a manifes-
tation of the efficiency of the antitumour immune
response.
Our immunohistochemical analysis of breast can-
cer has shown that some epithelial elements within
the tumour also appear to express CD1a antigen
besides professional antigen-presenting cells. This is
similar to our recent findings regarding metaplasia–
adenocarcinoma progression in Barrett’s oesopha-
gus,5,6 which led us to hypothesize a possible
co-stimulatory effect of this molecule on the func-
tional immune response.7
The present data suggest that evaluation of CD1a
expression at the LN level by means of molecular
diagnostic analyses might help to address the presence
of occult micrometastases. In addition, these results
support the hypothesis that a greater number of CD1a+
mononuclear cells in the tumour node microenviron-
ment may lead to the initiation of a functional host
response to the malignancy.
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